Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metabolic changes due to iatrogenic hypogonadism in patients with prostate cancer: orchiectomy vs. triptorelin [Metaboliske ændringer hos patienter med prostatakræft som følge af iatrogen hypogonadisme: orkiektomi vs. triptorelin]

Trial Profile

Metabolic changes due to iatrogenic hypogonadism in patients with prostate cancer: orchiectomy vs. triptorelin [Metaboliske ændringer hos patienter med prostatakræft som følge af iatrogen hypogonadisme: orkiektomi vs. triptorelin]

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics

Most Recent Events

  • 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
  • 04 Apr 2016 Results comparing androgen status (n = 55) presented at The 98th Annual Meeting of the Endocrine Society.
  • 02 Apr 2016 Status changed from recruiting to completed, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top